NCGM Inc genomic cell analysis visualization

About NCGM Inc

About NCGM

NCGM Inc – Genomic Excellence

Founded in 2020 and headquartered in Apex, North Carolina, NCGM is a CAP- and CLIA-accredited genomic laboratory dedicated to advancing precision medicine through high-quality next-generation sequencing (NGS) services. NCGM partners with researchers, clinicians, and industry organizations worldwide to deliver reliable genomic insights that support scientific discovery, clinical decision-making, and innovation.

Our state-of-the-art laboratory is equipped with advanced sequencing technologies, including Illumina platforms and complementary systems for library preparation, quality control, and bioinformatics analysis. This comprehensive infrastructure enables NCGM to support a broad range of genomic applications, including whole-exome sequencing, whole-genome sequencing, targeted panel testing, prenatal screening, and oncology-focused genomic assays.

Quality is central to everything we do. Operating under CAP and CLIA standards, NCGM employs rigorous quality control procedures throughout the testing workflow—from sample processing and sequencing to data analysis and reporting. Secure, HIPAA-compliant data management systems further ensure the accuracy, reliability, and confidentiality of patient and research data.

NCGM actively collaborates with leading academic institutions, healthcare organizations, and research partners to advance genomic science and translate discoveries into meaningful clinical applications. Through these collaborations, we contribute to research initiatives, technology development programs, and studies aimed at improving patient outcomes.

We are equally committed to investing in our people. Ongoing training, professional development programs, workshops, and educational initiatives ensure that our team remains at the forefront of genomic technologies and emerging scientific advancements.

By combining advanced technology, scientific expertise, and an unwavering commitment to quality, NCGM continues to support the advancement of genomic medicine and contribute to improving healthcare outcomes worldwide.